ArticleBrain and behavior2025
Quantitative Susceptibility Mapping of Deep Grey Matter in MS: Association With Clinical Scores and Brain Volume Measures.
Article in Brain and behavior, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Iron accumulation in multiple sclerosis and implications for cognitive and clinical progression: a systematic review of advanced neuroimaging studies.Journal of neurology · 2026Pooled it
- Article
- Heterogeneous Deep Gray Matter Iron Deposition Patterns across Multiple Sclerosis Subgroups Defined by the Clinico-Radiological Paradox.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2026Article
- Quantitative Susceptibility Mapping of Deep Grey Matter in MS: Association With Clinical Scores and Brain Volume Measures.Brain and behavior · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
backgroundChanges in quantitative susceptibility mapping (QSM) of the deep grey matter (DGM) in multiple sclerosis (MS) are thought to reflect tissue damage invisible in conventional magnetic resonance imaging (MRI) sequences, such as iron-related neurodegeneration.
objectiveTo explore the associations of clinical scores and MRI-based volumes with QSM values in the DGM (thalamus, putamen, caudate, and pallidum) in a large cohort of people with MS, and to assess the predictive value of QSM values for clinical outcomes after three years.
methodsA total of 771 MS patients (clinically isolated syndrome (CIS): n = 35, relapsing-remitting: n = 637, progressive: n = 63) were scanned at 3T with T1-weighted, T2-FLAIR, and QSM sequences. All patients were included in the cross-sectional analyses examining the relationship of DGM QSM values with MRI variables and clinical scores. Normalized brain volume (NBV) was computed using SIENAX, while total lesion volume (TLV) was derived from the lesion segmentation tool, LST-AI. Clinical scores included the expanded disability status scale (EDSS), timed 25 foot walk (T25FW), Nine Hole Peg Test (9HPT), symbol digit modalities test (SDMT), and fatigue scale for motor and cognitive functions (FSMC). In the longitudinal analyses, only clinical scores were included, with various sample sizes across different clinical scores (N
resultsAt baseline, after adjusting for confounding factors, higher QSM values in the basal ganglia were significantly associated with greater TLV (β = 0.14 - 0.17; p < 0.001), higher clinical severity (EDSS: β = 0.13 - 0.19, p < 0.001), worse dexterity (NHPT: β = 0.14 - 0.16, p = 0.02), and lower cognitive functioning (SDMT: β = -0.13 - -0.15, p = 0.03). In contrast, lower thalamic QSM values were associated with greater TLV (β = -0.07; p = 0.03). Unlike regional volumes, DGM QSM values did not predict clinical outcomes at follow-up.
conclusionDGM QSM values are robustly associated with MS severity and TLV cross-sectionally. However, our large-scale longitudinal analysis suggests that DGM QSM values lack prognostic value for short-term clinical progression in early-stage MS.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.